<DOC>
	<DOCNO>NCT00248456</DOCNO>
	<brief_summary>This study evaluate efficacy safety calcipotriol plus betamethasone dipropionate ointment compare calcipotriol ointment treatment patient psoriasis vulgaris duration 4 week . The study focus percentage change psoriasis area severity index ( PASI ) baseline end week 4 .</brief_summary>
	<brief_title>Efficacy Safety Calcipotriol Plus Betamethasone Dipropionate Ointment Patients With Psoriasis Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Clinical diagnosis psoriasis vulgaris stable condition Extent least 10 % one body region Amenable topical therapy maximum 100 g/week investigational product Patients 30 % body surface area involve Patients facial psoriasis need treatment Patients need treatment scalp psoriasis WHO group IV topical corticosteroid , tretinoin topical vitamin D derivatives Patients unstable form psoriasis include guttate , erythrodermic , pustular , arthritis psoriasis Systemic treatment psoriasis corticosteroid therapy Systemic antipsoriatic treatment ( e.g . corticosteroid , immunosuppressive drug , tretinoin , antibiotic , phototherapy calcium agent ) within 4 week prior visit 1 ; topical antipsoriatic treatment ( e.g . keratolytics , topical corticosteroid , topical vitamin D derivative , anthralin , crude coal tar , etc ) within previous 2 week period Patients plan exposure phototherapy may affect psoriasis study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2008</verification_date>
</DOC>